Properties of the Novel Chinese Herbal Medicine Formula Qu Du Qiang Fei I Hao Fang Warrant Further Research to Determine Its Clinical Efficacy in COVID-19 Treatment
- PMID: 33613814
- PMCID: PMC7894031
- DOI: 10.1089/acu.2020.1466
Properties of the Novel Chinese Herbal Medicine Formula Qu Du Qiang Fei I Hao Fang Warrant Further Research to Determine Its Clinical Efficacy in COVID-19 Treatment
Abstract
Introduction: COVID-19, the infectious disease induced by the virus severe acute respiratory syndrome-related coronavirus-2, has caused increasing global health concerns, and novel strategies to prevent or ameliorate the condition are needed. Traditional Chinese Medicine (TCM) herbal formulas have been used in the treatment of epidemics in China for over 2000 years. This study investigated the therapeutic effects of Qu Du Qiang Fei I Hao Fang (QDQF1) "Eliminating Virus and Strengthening Lung-No.1 Formula," in the treatment and prevention of COVID-19. QDQF1 consists of Shēng Huáng Qí, Běi Shā Shēn, Chuān Jié Gěng, Zhì Fáng Fēng, Qīng Lián Qiáo, Jīn Yín Huā, Bǎn Lán Gēn, Chǎo Cāng Zhú, Zǐ Huā Dì Dīng, and Shēng gān căo. Materials and Methods: A literature survey was performed by conducting systematic electronic searches in PubMed, Science Direct, Google Scholar, and in books. Results: Each herb in this formula has long been used to treat various diseases due to their pharmacologic, antiviral, anti-inflammatory, and antimicrobial effects that inhibit microbial adherence to mucosal or epithelial surfaces, inhibit endotoxin shock, and selectively inhibit microbial growth. Conclusion: The herbs chosen for the QDQF1 formula have been historically paired, and cast a wide net over the potential COVID-19 symptomatology. Their combined functions provide comprehensive and balanced therapeutics from both TCM and allopathic perspectives. Individual herbs and herbal combinations are analyzed for their applicability to pertinent TCM patterns of COVID-19 presentations, including heat and cold patterns, damp and phlegm syndromes, toxicity, and deficiency patterns. A further study in a randomized, double-blind, and placebo-controlled trial of QDQF1 is recommended to assess its therapeutic efficacy in the treatment of COVID-19.
Keywords: COVID-19; Chinese herbal medicine; SARS-CoV-2; Traditional Chinese Medicine; formula QDQF1; immune response.
Copyright 2021, Mary Ann Liebert, Inc., publishers.
Conflict of interest statement
No competing financial interests exist.
Similar articles
-
Traditional Chinese Medicine Induced Liver Injury.J Clin Transl Hepatol. 2014 Jun;2(2):80-94. doi: 10.14218/JCTH.2014.00003. Epub 2014 Jun 15. J Clin Transl Hepatol. 2014. PMID: 26357619 Free PMC article. Review.
-
Traditional Chinese Medicine and herbal hepatotoxicity: a tabular compilation of reported cases.Ann Hepatol. 2015 Jan-Feb;14(1):7-19. Ann Hepatol. 2015. PMID: 25536637 Review.
-
Anti-inflammatory and Antimicrobial Effects of Heat-Clearing Chinese Herbs: A Current Review.J Tradit Complement Med. 2014 Apr;4(2):93-8. doi: 10.4103/2225-4110.126635. J Tradit Complement Med. 2014. PMID: 24860732 Free PMC article. Review.
-
Prescription patterns of Chinese herbal products for post-surgery colon cancer patients in Taiwan.J Ethnopharmacol. 2014 Aug 8;155(1):702-8. doi: 10.1016/j.jep.2014.06.012. Epub 2014 Jun 16. J Ethnopharmacol. 2014. PMID: 24945402
-
The efficacy and safety of Chinese herbal medicine Shen-Qi Hua-Yu formula in patients with diabetic lower extremity artery disease: Study protocol of a multi-center, randomized, double-blind, placebo-controlled trial.Medicine (Baltimore). 2020 Jan;99(3):e18713. doi: 10.1097/MD.0000000000018713. Medicine (Baltimore). 2020. PMID: 32011447 Free PMC article.
Cited by
-
Emergency Protective Measures and Strategies of COVID-19: From Lifestyle to Traditional Chinese Medicine.Clin Complement Med Pharmacol. 2023 Sep;3(3):100089. doi: 10.1016/j.ccmp.2023.100089. Epub 2023 Apr 6. Clin Complement Med Pharmacol. 2023. PMID: 37342312 Free PMC article. Review.
-
Effectiveness of Lianhua Qingwen Granule and Jingyin Gubiao Prescription in Omicron BA.2 Infection and Hospitalization: A Real-World Study of 56,244 Cases in Shanghai, China.Chin J Integr Med. 2025 Jan;31(1):11-18. doi: 10.1007/s11655-024-3901-7. Epub 2024 Jun 24. Chin J Integr Med. 2025. PMID: 38910189
References
-
- Mcintosh K Coronaviruses: A comparative review. Curr Top Microbiol Immunol./Ergebnisse der Mikrobiologie und Immunitätsforschung. 1974;63:85–129
-
- World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. Pediatria i Medycyna Rodzinna. 2020;16:9–26
-
- Q&A on coronaviruses (COVID-19). World Health Organization. Online document at: https://www.who.int/news-room/q-a- detail/q-a-coronaviruses Accessed February10, 2020
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous